With unrivaled expertise and extensive experiences in immunology, Creative Biolabs has developed an advanced T-Scan platform to help our clients accelerate their T cell research by providing end-to-end excellent services. We are dedicated to assisting our clients with the identification and characterization of functional antigens or targets recognized by T cells, systematic discovery of T cell epitopes.
As a critical role in adaptive immunity, T cells can recognize the specific antigens presented on antigen-presenting cells (APCs) and play helper or cytotoxicity functions to mediate protection from pathogens and cancers. Antigen is proteolyzed by the proteasome and loaded to the MHC molecule, then presented on the cell surface of APC. T cells are activated once TCR recognizes the peptide-MHC complex. CD8 positive T cells proliferate to cytotoxic T cells and kill the target cells with the same antigen. CD4 positive T cells proliferate to helper T cells and activate B cells with the same antigen. The activated B cells can proliferate to be plasma cells to produce antibodies (see Fig.1). When T cells recognize autoantigens, autoimmunity happens. Hence, understanding the T cell antigens or epitopes is necessary to help scientists explore the relationship between T cell antigens and human health. In addition, the identification of T cell epitopes provides strategic insights for immunotherapies.
Fig.1 T cell activation by antigens. (Wolfert, 2013)
To discover novel antigens of TCRs from viral or human genome-wide libraries, our scientists developed an advanced T-Scan platform, a T cell-based, high-throughput screening approach to identify functional T cell-specific epitopes for studying T cell responses. The T-Scan platform consists of T cells of interest and target cells expressed with a library of candidate antigens. The antigens are endogenously processed and presented on MHC molecules. Upon recognition by T cells, target cells are activated and the T-Scan reporter (granzyme B) will be used for FACS sorting to isolate the activated target cells. The recognized antigens displayed on target cells are identified by PCR and sequenced with Next Generation Sequencing technology (see Fig.2).
Fig.2 Design of T-Scan platform. (Kula, 2019)
Our T-Scan platform can be widely applied in various areas such as infectious disease, autoimmune disease, and cancer immunology. In an infectious disease, T-Scan can be used to profile the T cell epitopes which provide insights for vaccine design. In the autoimmune area, T-Scan can be used to study the features of auto-reactive T cell antigens. In cancer immunology, T-Scan can be used to identify and characterize the neoantigens in cancer patients which can guide personalized vaccine design. Also, T-Scan can identify the genome-wide antigens recognized by the TCRs that are responsive to tumors. Furthermore, T-Scan can be used to screen the therapeutic TCRs with off-target toxicities in patients.
Fig.3 Applications of T-Scan platform. (Kula, 2019)
With this powerful platform, Creative Biolabs is dedicated to the high-throughput discovery of the functional targets/antigens of T cells. We are committed to helping our clients explore the functionality of T cells in various areas and develop novel therapeutics. If you have any requirements, please feel free to contact us to learn more.
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE